TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25436319
Drug: Combined Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Therapy (HAIC plus systemic chemotherapy)
Study: 25436319
Drug: Monotherapy (systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (systemic chemotherapy alone)
Study: 21086017
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiotropium bromide therapy for 4 years
Study: 20380708
Drug: Activ-L Artificial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activ-L Artificial Disc
Study: 20380708
Drug: Charité Artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Charité Artificial Disc [DePuy Spine] or ProDisc-L Total Disc Replacement [Synthes Spine]
Study: 16105333
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg intramuscularly (i.m.) 30 min before the procedure
Study: 16105333
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg i.m. 30 min before the procedure, together with local infiltration of the cervix with lignocaine 1% (10 mL)
Study: 16105333
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg i.m. 30 min before the procedure together with local infiltration of the cervix with lignocaine 1% (10 mL) and paracervical block with lignocaine 1% (5 mL)
Study: 11788216
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (1-mg nicotine)
Study: 11788216
Drug: Cigarette smoke
Normalized name: cigarette smoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoke (1-mg nicotine, 12 mg tar)
Study: 10037314
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (GM) administered continuously at 1.5 mg/kg per hour from the beginning of anesthesia until the third postoperative day (preop GM group)
Study: 10037314
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (GM) administered continuously at 1.5 mg/kg per hour from the end of surgery and for the same postoperative period (postop GM group)
Study: 10037314
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (GM) administered in the preop GM group
Study: 2309827
Drug: Continuous ethinyl
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous ethinyl estradiol and norethindrone acetate (various doses)
Study: 2309827
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.625 mg and medroxyprogesterone acetate 10 mg
Study: 48835
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and insulin
Study: 25213161
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg once daily for weeks 1-3 of each 4-week cycle
Study: 24187864
Drug: BHY group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHY group (BHY instant granules, 6 g, twice per day)
Study: 24187864
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (piracetam, 0.8 g, 3 times per day)
Study: 16420200
Drug: Simvastatin up
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin up to 20 mg/d for 15 weeks
Study: 7698862
Drug: Bioabsorbable osteosynthetic
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable osteosynthetic implants of ultra high strength poly-L-lactide (PLLA)
Study: 3556192
Drug: Buccal nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal nifedipine 20 mg
Study: 27110823
Drug: Synthetic unimolecular
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic unimolecular pentavalent carbohydrate vaccine (Globo‐H, GM2, sTn, TF, and Tn) conjugated to keyhole limpet haemocyanin (KLH) mixed with immunological adjuvant QS‐21 at doses of 25, 50, and 100 mcg.
Study: 23687780
Drug: Nurse-led case
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led case management program (monthly telephone calls, motivational interviewing for lifestyle change, home BP monitoring, dosettes for medication administration)
Study: 16423519
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort (PM235) - lower dose (0.12% hypericine)
Study: 16423519
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort (PM235) - higher dose (0.18% hypericine)
Study: 16423519
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's Wort (PM235) - pooled high and low doses
Study: 11727665
Drug: GTN patches
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN patches (0.4‐0.8 mg/h)
Study: 9228496
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal estradiol (0.050 mg/day)
Study: 9228496
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral conjugated estrogens (0.625 mg/day)
Study: 30658096
Drug: rIPC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIPC treatment (n=8)
Study: 23988179
Drug: Pharmacotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy plus cognitive-coping therapy (PCCT)
Study: 20607405
Drug: Pantoprazole high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole high dose (1.2 mg/kg)
Study: 20607405
Drug: Pantoprazole low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole low dose (0.6 mg/kg)
Study: 3125025
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg and misoprostol 400 micrograms bid
Study: 29494423
Drug: Genotype-guided pharmacogenetics
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided pharmacogenetics guided (PHG) warfarin dosing
Study: 29494423
Drug: Clinically guided
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically guided non pharmacogenetics guided (NPHG) warfarin dosing
Study: 27016718
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional Er:YAG laser at 11.2 mJ per laser channel with 1% density, MAL 160 mg/g, 180 min incubation
Study: 27016718
Drug: MAL 80
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAL 80 and 160 mg/g
Study: 23852294
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral treatment (HAART)
Study: 20186439
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg kg(‐1)
Study: 20186439
Drug: Lidocaine 1
Normalized name: lidocaine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1 mg kg(‐1) with remifentanil 1 microg kg(‐1) min(‐1)
Study: 20186439
Drug: Rocuronium 1
Normalized name: rocuronium 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1 mg kg(‐1)
Study: 20186439
Drug: Propofol 2‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2‐2.5 mg kg(‐1)
Study: 18243569
Drug: Probiotic drink
Normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic drink containing Lactobacillus casei DN‐114 001 at 10(8) CFU/g
Study: 15891924
Drug: Midazolam (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.6 mg/kg)
Study: 15891924
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (25 mg/kg)
Study: 1518258
Drug: Mean relative
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean relative dose greater than 0.9
Study: 30176897
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose primaquine (0.5 mg base/kg body weight) for 14 days
Study: 30176897
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose primaquine (0.25 mg/kg) for 14 days
Study: 27629871
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2 g daily
Study: 18580611
Drug: Four injections
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four injections of ALVAC-HIV vaccine (vCP1452) at weeks 0, 4, 8, 20
Study: 18580611
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of ALVAC-HIV vaccine (vCP1452) at weeks 4, 8, 20
Study: 18580611
Drug: Four injections
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four injections of ALVAC-HIV vaccine (vCP1452)
Study: 18580611
Drug: Three injections
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three injections of ALVAC-HIV vaccine (vCP1452)
Study: 18580611
Drug: Immunization (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunization (both three and four injections)
Study: 10778521
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg + nimesulide 100 mg
Study: 9345406
Drug: High-dose Betaseron
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Betaseron
Study: 9345406
Drug: Low-dose Betaseron
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Betaseron
Study: 1828683
Drug: Picotamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (300 mg x 3 daily)
Study: 31776820
Drug: Intraoperative iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative iodine (5 mL of 0.25% povidone-iodine applied at 2 stages)
Study: 31776820
Drug: Preoperative topical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative topical antibiotics (administered 3 days before surgery)
Study: 31898677
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch (30 gm daily)
Study: 30335422
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy for PTSD
Study: 30335422
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and behavioral therapies for OCD
Study: 30335422
Drug: Psychodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic therapy in a naturalistic setting
Study: 25825091
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine (CHX) mouth rinse used twice daily for one week
Study: 17937843
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (10 mg/kg first dose, followed by two doses of 5 mg/kg each at 24 hr intervals)
Study: 17937843
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (0.2 mg/kg at 24 hr intervals)
Study: 15200437
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of iron (III) sucrose
Study: 15200437
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of iron (III) sucrose
Study: 8796137
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg fenfluramine
Study: 8796137
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fenfluramine
Study: 8796137
Drug: CRH injection
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH injection
Study: 1620826
Drug: rTPA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTPA plus heparin
Study: 1620826
Drug: rTPA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTPA with or without heparin
Study: 6538427
Drug: Cimetidine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1000 mg) with phenazone (15 mg/kg)
Study: 6538427
Drug: Metronidazole (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1000 mg) with phenazone (15 mg/kg)
Study: 30853816
Drug: Extended venous
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended venous thromboembolism prophylaxis (vte) with low molecular weight heparin (lmwh)
Study: 27322798
Drug: Pioglitazone, 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone, 45 mg/d
Study: 22137494
Drug: Estriol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol (2 mg/day for 8 weeks)
Study: 17906762
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil capsules 1 g/day
Study: 17906762
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil capsules 2 g/day
Study: 10036609
Drug: 4.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 mg/kg caffeine (C)
Study: 10036609
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of behavioral reinforcement and caffeine (B + C)
Study: 26882061
Drug: Topical dilute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dilute epinephrine (DE) 1% with lidocaine 1:100,000
Study: 26882061
Drug: Topical phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical phenylephrine 2.5%
Study: 25534490
Drug: Alprostadil liposomal
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil liposomal preparation
Study: 31957889
Drug: Manual gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual gel testing
Study: 26912491
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg DHA/d
Study: 22251828
Drug: Neurocognitive habilitation
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive habilitation therapy (group therapy intervention for foster and adoptive caregivers and their children)
Study: 15728081
Drug: IV saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline (group L)
Study: 10541912
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) with anticholinergic (scopolamine) and alpha-adrenergic blocking agents (prazosin)
Study: 10541912
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) with beta-adrenergic blocking agent (propranolol)
Study: 9084534
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 3 mg/kg/h after 0.3 mg/kg bolus injection (Group A)
Study: 9084534
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 4 mg/kg/h after 0.4 mg/kg bolus injection (Group B)
Study: 9084534
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 5 mg/kg/h after 0.5 mg/kg bolus injection (Group C)
Study: 6980404
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (4.5 g/day)
Study: 8590162
Drug: H2-receptor blockers
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor blockers (ranitidine or famotidine)
Study: 7067923
Drug: Repeat action
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat action tablet containing 1 mg of azatadine maleate and 60 mg of d-pseudoephedrine sulfate
Study: 7067923
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet of 60 mg of d-pseudoephedrine sulfate
Study: 7067923
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet of 1 mg of azatadine maleate
Study: 27228369
Drug: Ovulation induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovulation induction treatment
Study: 26218723
Drug: Polypodium leucotomos
Normalized name: Polypodium leucotomos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypodium leucotomos (PLE) supplementation after photodynamic therapy (PDT)
Study: 20376059
Drug: Heparin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (0.5 IU kg⁻¹ h⁻¹ in TPN solutions)
Study: 20376059
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin (TPN fluids without heparin)
Study: 19034975
Drug: High-dose acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acetaminophen and NSAIDs ingestion (group I)
Study: 11142412
Drug: Topical DFMO
Normalized name: DFMO
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical DFMO ointment (10% w/w) applied twice daily for 6 months
Study: 11142412
Drug: Placebo hydrophilic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo hydrophilic ointment applied twice daily for 6 months
Study: 8104062
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate 60 mg (single im injection)
Study: 8104062
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide 200 micrograms bid (aerosol spray)
Study: 8104062
Drug: Terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 60 mg daily (tablets)
Study: 3542441
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (PGE2) 0.5 mg qid
Study: 18249325
Drug: Aprotinin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (loading dose of 2 x 10(6) KIU followed by continuous infusion at 5 x 10(5) KIU/h until skin closure)
Study: 10781982
Drug: Imipenem/cilastatin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (1.5 g daily)
Study: 10781982
Drug: Meropenem (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (3 g daily)
Study: 2866715
Drug: 0.25% betaxolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% betaxolol, treated twice daily for six weeks
Study: 2866715
Drug: Placebo, treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, treated twice daily for six weeks
Study: 29137956
Drug: 19-Gy high-dose-rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19-Gy high-dose-rate brachytherapy (HDR-BT)
Study: 19889807
Drug: Legume-enriched, low-glycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Legume-enriched, low-glycemic index diet (250 g/d, GI 38)
Study: 12672185
Drug: Etanercept (Enbrel®)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (Enbrel®) administered subcutaneously twice weekly
Study: 1516500
Drug: Morning NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning NPH insulin (22 +/- 1 IU) plus 3.5 mg glibenclamide twice a day
Study: 1516500
Drug: Bedtime NPH
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime NPH insulin (22 +/- 1 IU) plus 3.5 mg glibenclamide twice a day
Study: 31306167
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal methods (DMPA-IM, norethisterone enanthate, implants)
Study: 25475196
Drug: IV magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV magnesium sulfate 1 g just before the procedure
Study: 23268365
Drug: 0.5% nitroglycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% nitroglycerine gel
Study: 23268365
Drug: 1.25% nitroglycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25% nitroglycerine gel
Study: 1467110
Drug: Interpleural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpleural morphine 2.5 mg i.p. and normal saline i.v. (group I)
Study: 1467110
Drug: Morphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2.5 mg i.v. and i.p. saline (group II)
Study: 6420025
Drug: Cimetidine 600
Normalized name: cimetidine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 600 mg p.o.
Study: 6420025
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg IM
Study: 6420025
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg IM preceded by cimetidine 600 mg p.o.
Study: 6420025
Drug: Cimetidine 600
Normalized name: cimetidine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 600 mg p.o. and Morphine 10 mg IM